GroPep starts Phase 1 infertility trial

sponsible for instructing the mother's immune system to tolerate the implanting embryo. Preclinical studies previously reported by GroPep have shown that a single intravaginal dose of PV903 halves the miscarriage rate in a mouse model of reproductive failure that shares many features with recurrent miscarriage in humans. A Clinical Research Study conducted in the last six months has enabled GroPep to identify and measure a range of immune cells from the cervix of healthy women volunteers. Changes in these cells after the introduction of PV903 are expected to indicate whether the treatment is effective. GroPep CEO Mr Bob Finder said he was delighted at the commencement of the PV903 clinical trial. He further noted, "This trial represents the culmination of several years work by GroPep and our collaborators to understand the role of PV903 in immune-based infertility, undertake toxicology studies and develop a stable gel-based formulation."

"As this is a potential first-in-class product, GroPep has had to develop new methods to measure the effect of PV903 on the immune system. We are now in a position to initiate the clinical phase of this program, which has the potential to offer the first drug treatment for recurrent miscarriage", Mr Finder added. The following information is provided regarding the trial. Name of Trial

A Phase Ia, randomised, double-blind, placebo-controlled, sequential single-dose escalating trial in healthy adult female volunteers to evaluate the short-term safety, tolerability and preliminary immune activity of vaginally administered PV903 gel.


Contact: Mr Tony Mitchell
Research Australia

Page: 1 2

Related medicine news :

1. GroPep awarded key patent for infertility treatment in Europe
2. GroPep completes final milestone of the path malaria vaccine initiative
3. GroPep to pursue promising asthma drug following preclinical study results
4. GroPep licenses technology to TGR BioSciences
5. GroPep news: Key psoriasis patent granted in Japan and new asthma patent filed for GroPep drug
6. Coffee jump-starts short-term memory
7. Epidemiology in Europe: the problem starts in childhood
8. GSK announces launch of largest ever Phase III trial in lung cancer treatment
9. Phase II study shows combination improves survival of metastatic melanoma patients
10. MacroChem completes patient enrollment for Phase II trial of EcoNail for treatment of onychomycosis
11. Drug combination proves effective against myeloma in Phase I trial

Post Your Comments:

(Date:9/14/2019)... CITY, Calif. (PRWEB) , ... ... ... Molecular Imaging Society (WMIS) showcased several first-in-human studies on the detection and ... Montreal. Highlighting two examples of these ground-breaking studies were noninvasive detection of ...
(Date:9/11/2019)... ... September 11, 2019 , ... Workplace injuries ... struggled to solve injury risks which lead to musculoskeletal disorders (MSDs). , ... developed by the team at Soter Analytics helps avoid ergonomic injury ...
(Date:9/11/2019)... (PRWEB) , ... September 11, 2019 , ... ... will exhibit at the 2019 AHIMA Health Data and Information Conference in Chicago, ... stop by booth #505 to learn more about GRM’s healthcare information management ...
(Date:9/11/2019)... ... ... Ahipoki is excited to announce a new vegan and gluten free alternative ... and poke bowl fans alike. Ahimi is made of five simple ingredients including ... to tuna, Ahipoki customers will now have a vegan option when building ...
(Date:9/11/2019)... PASADENA, Calif. (PRWEB) , ... September 10, 2019 ... ... been named Top Doctors by Pasadena Magazine. These physicians have been recognized among ... in their respective pediatric subspecialties:, Robert H. Cho, ...
Breaking Medicine News(10 mins):
(Date:9/17/2019)... ... September 17, 2019 , ... Scientists writing in ... agents to stop the progressive destruction of joint cartilage in osteoarthritis are “on ... hand and upper limb orthopedic surgeon Alejandro Badia, MD , founder and ...
(Date:9/17/2019)... OCALA, Fla. (PRWEB) , ... September 17, 2019 , ... ... offering dental implant placement and restorations in one office. Dental implants are ... and prevent bone loss. , Dental implants have a high success rate when placed ...
(Date:9/17/2019)... OBISPO, Calif. (PRWEB) , ... September 17, 2019 , ... Summer is a time for ... it is good for our teeth and gums. Dr. Douglas Ng, family dentist in ... Warm weather is the time for ice cream, and popsicles and ice-filled cold drinks to ...
Breaking Medicine Technology:
Cached News: